Literature DB >> 18201372

B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.

F Lavie1, C Miceli-Richard, M Ittah, J Sellam, J-E Gottenberg, X Mariette.   

Abstract

We investigated B-cell activating factor of the tumour necrosis factor family (BAFF) level in peripheral blood mononuclear cells (PBMCs), monocytes and T cells from patients with primary Sjögren's syndrome (pSS) and controls both ex vivo and in vitro after cytokine stimulation. PBMCs, monocytes and T cells were isolated from 15 patients with pSS and 17 controls. Cells were cultured alone or with interferon (IFN)alpha, IFNgamma and interleukin 10 (IL-10). T cells were stimulated with phytohaemagglutin and anti-CD3. BAFF protein was assessed by enzyme-linked immunosorbent assay. Ex vivo, no difference was observed in BAFF mRNA level in PBMCs and monocytes from patients and controls. Blood monocytes were the main cell type secreting BAFF both in patients and controls. In vitro, after IFNalpha stimulation, BAFF mRNA level was significantly higher in cells from patients than from controls (63.8 versus 20.7, P = 0.03). T cells from patients secreted a higher level of BAFF protein than those from healthy donor cells (17.4 versus 2.9 pg/ml, respectively, P = 0.04) but at a lower level than that from monocytes. Stimulation of T cells did not change BAFF secretion level. The induction of Th17 cells showed no increased BAFF expression. In conclusion, similar to epithelial cells, blood monocytes in patients with pSS show increased production of BAFF under IFNalpha, which confirms the involvement of IFNalpha in pSS. BAFF expression is also increased in blood T cells of such patients, independently of T-cell stimulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201372     DOI: 10.1111/j.1365-3083.2007.02049.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  29 in total

Review 1.  Pathogenesis of Sjögren's syndrome.

Authors:  Nikolay P Nikolov; Gabor G Illei
Journal:  Curr Opin Rheumatol       Date:  2009-09       Impact factor: 5.006

2.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

Review 3.  Autoimmunity at the ocular surface: pathogenesis and regulation.

Authors:  M E Stern; C S Schaumburg; R Dana; M Calonge; J Y Niederkorn; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2010-05-19       Impact factor: 7.313

4.  A pathogenetic role for IL-21 in primary Sjögren syndrome.

Authors:  Seung-Ki Kwok; Jennifer Lee; Di Yu; Kwi Young Kang; Mi-La Cho; Hae-Rim Kim; Ji Hyeon Ju; Sang-Heon Lee; Sung-Hwan Park; Ho-Youn Kim
Journal:  Nat Rev Rheumatol       Date:  2015-01-13       Impact factor: 20.543

5.  Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring.

Authors:  Kristopherson Lustosa Augusto; Eloisa Bonfa; Rosa Maria Rodrigues Pereira; Cleonice Bueno; Elaine Pires Leon; Vilma Santos Trindade Viana; Sandra Gofinet Pasoto
Journal:  Clin Rheumatol       Date:  2015-09-14       Impact factor: 2.980

Review 6.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

Review 7.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

Review 8.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

9.  Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system.

Authors:  Jiahui Yang; Richard Pospisil; Rose G Mage
Journal:  Dev Comp Immunol       Date:  2009-01-03       Impact factor: 3.636

Review 10.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.